Benzinga's Top #PreMarket Gainers

shares spiked 46.05 percent to $6.66 in pre-market trading following Q3 earnings report and sale of stake in Shanghai Meining Computer Software.

shares surged 20.10 percent to $4.60 in pre-market trading after the company reported that its Phase 3 binimetinib trial has met primary endpoint for NRAS-mutant melanoma.

shares climbed 9.49 percent to $5.42 in pre-market trading after surging 12.41 percent on Tuesday.

shares jumped 8.64 percent to $10.31 after gaining 4.29 percent on Tuesday.

rose 8.61 percent to $43.50 in pre-market trading. Roth Capital maintained SolarCity with a Buy and raised the price target from $55.00 to $65.00.